Zhi Tong Cai Jing·2026-01-14 22:45Core Viewpoint - 康龙化成 plans to issue a total of 58.44 million new H-shares at a price of HKD 22.82 per share, representing an approximate discount of 8.50% from the market price on January 14, 2026 [1] Group 1: Share Issuance Details - The new shares will account for approximately 16.57% of the total issued H-shares and about 3.19% of the total issued shares after the completion of the placement [1] - The total expected proceeds from the share placement are approximately HKD 1.334 billion, with net proceeds estimated at HKD 1.319 billion, translating to a net price of about HKD 22.56 per share [1] Group 2: Use of Proceeds - Approximately 70% of the proceeds will be allocated to project construction to enhance the company's laboratory service facilities, drug process development, and production capacity [1] - About 10% of the proceeds will be used to repay bank loans and other borrowings to optimize the company's capital structure [1] - Approximately 20% will be utilized to supplement working capital and for other general corporate purposes [1]